Health software company Volpara Health Technologies (ASX:VHT)
reports their trial in breast cancer screening had excellent results in the second-round.
The study used Volpara®Density™ software to assess breast density. The results showed a significant reduction in interval cancers in those women being selected for breast MRI. False-positive rate significantly reduced relative to first results two years ago.
Shares in Volpara Health Technologies (ASX:VHT)
are trading 2.3 per cent higher at $1.32.